24 jul: Bobler fra dybet fik hammerslag på rekordpriser ved nyligt afhold..
01 aug: Mercedes CLS Shooting Brake på vej til Danmark
31-07-2012 15:43:00

Auxilium Swings to First Quarterly Profit as Revenue Grows

Relateret indhold
Relateret debat
22 apr - 
Jeg fik aldrig postet denne nyhed: "GSK buys out Novart..

By Chelsea Stevenson

Auxilium Pharmaceuticals Inc. (AUXL) posted its first profitable period in the second quarter as the specialty biopharmaceutical company saw double-digit revenue growth.

The company raised its revenue estimate for the year to $310 million to $332 million, from $293 million to $315 million.

The company's two main drugs are Xiaflex, which is currently allowed in the U.S. and Europe to treat some adults suffering from Dupuytren's contracture in a person's fingers that aren't able to fully extend from the palm, and testosterone replacement therapy Testim.

Auxilium plans to file with the U.S. Food and Drug Administration seeking approval for the potential use of Xiaflex in the treatment of certain penile dysfunction by the end of 2012. Analysts at RBC Capital Markets estimate the potential U.S. market for Peyronie's disease stands at more than $100 million. Meanwhile, the company has a deal with GlaxoSmithKline PLC (GSK) to promote Testim.

"For the remainder of 2012 and beyond, we will continue to focus on delivering excellence in commercial execution and we anticipate a positive additional impact from GlaxoSmithKline's efforts on Testim's growth," Chief Executive Adrian Adams said. "We also look forward to filing the sBLA [supplemental biologics license application] for Xiaflex for the treatment of Peyronie's disease by the end of the year as we seek to obtain FDA approval for this indication."

For the period ended June 30, Auxilium posted a profit of $7.7 million, of 16 cents a share, compared with a loss of $5.1 million, of 11 cents a share, in the year-ago period. The latest quarter includes stock-based compensation expense of $3.9 million, compared with a $4 million expense last year.

Revenue rose 19% to $78.2 million, primarily due to increases in U.S. sales where Xiaflex revenue climbed 21% and Testim revenue rose 26%.

Gross margin narrowed to 77% from 78% due to the high margin catch-up amortization that was recognized last year from Xiaflex.

By drug, Auxilium is raising its full-year guidance for global Testim revenue to $245 million to $255 million from $225 million to $235 million but cut its outlook for global Xiaflex revenue to $65 million to $77 million from $68 million to $80 million.

Shares closed Monday at $25.77 and were inactive premarket. The stock is up 44% in the past three months.

Write to Chelsea Stevenson at chelsea.stevenson@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 31, 2012 09:43 ET (13:43 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Tivoli/CEO: Ny sæson og Tivoli Hjørnet øger omsætningen

23-04-2018 13:39:42
Den nye sæson hos forlystelsesparken Tivoli, Vinter I Tivoli, har sammen med åbningen af Tivoli Hjørnet bidraget til, at omsætningen er steget i første kvartal 2018.Det vurderer Lars Liebst, der er administrerende direktør i Tivoli. - Vi har haft åbent til Vinter i Tivoli og åbnet vores hjørne, og det har været gode ting. Det kan man se på omsætningen, siger Lars Liebst til Ritzau Finans.Nettoomsæ..

Vestas-konkurrent: Møllepriser er faldet 13 pct. på årsbasis

23-04-2018 07:00:55
Den amerikanske Vestas-konkurrent GE Renewable Energy melder om fortsat prispres, hvilket selskabet forsøger at kompensere for gennem omkostningsreduktioner. I første kvartal faldt priserne på nye mølleenheder til ordrebogen med 13 pct. i forhold til samme periode sidste år. Det sagde finansdirektøren for General Electric, som GE Renewable Energy er en del af, Jamie Miller, fredag på en telekonfer..

Bavarian: Udenlandske kapitalfonde øger væddemålet på kursfald

20-04-2018 16:36:15
En række kapitalfonde har onsdag og torsdag øget sine shortpositioner i biotekselskabet Bavarian Nordic. Det viser en række indberetninger til Finanstilsynet. Torsdag har Capital Partners øget sin shortposition til 0,62 pct. af aktierne fra 0,54 pct. Ligeledes har AHL Partners øget sin shortposition til 1,31 pct. af Bavarian-aktierne. Tidligere havde kapitalfonden shortet 1,20 pct.Arrow Street øge..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas-konkurrent: Møllepriser er faldet 13 pct. på årsbasis
2
Aktier/tendens: Topdanmark kan få hovedrolle i neutralt marked
3
OK18: Overraskede lønmodtagere venter på svar fra staten
4
Milliardsalg af L'easy vakler - citat
5
Pandora/Carnegie: Løfter kursmålet til 700 kr.

Relaterede aktiekurser

Glaxosmithkline PLC ORD .. 1.440,60 0,7% Stigning i aktiekurs
GlaxoSmithKline PLC 40,00 0,3% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. april 2018 15:44:45
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180423.5 - EUROWEB1 - 2018-04-23 15:44:45 - 2018-04-23 15:44:45 - 1 - Website: OKAY